Atossa Therapeutics
ATOS
About: Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Employees: 13
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
91% more call options, than puts
Call options by funds: $174K | Put options by funds: $91K
0% more funds holding
Funds holding: 83 [Q1] → 83 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 28
5.43% less ownership
Funds ownership: 21.95% [Q1] → 16.53% (-5.43%) [Q2]
7% less capital invested
Capital invested by funds: $19.1M [Q1] → $17.7M (-$1.36M) [Q2]
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
Financial journalist opinion
Based on 4 articles about ATOS published over the past 30 days
